New York State Common Retirement Fund
FOLD

New York State Common Retirement Fund’s Amicus Therapeutics FOLD Stock Holding History

New York State Common Retirement Fund’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-88,516
Closed -$1.28M – 3228
2026
Q1 		$1.28M Hold
88,516
– – ﹤0.01% 1571
2025
Q4 		$1.26M Sell
88,516
-234,240
-73% -$2.3M ﹤0.01% 1613
2025
Q3 		$2.54M Buy
322,756
+83,872
+35% +$597K ﹤0.01% 1353
2025
Q2 		$1.37M Sell
238,884
-17,600
-7% -$114K ﹤0.01% 1545
2025
Q1 		$2.09M Sell
256,484
-686,630
-73% -$6.35M ﹤0.01% 1363
2024
Q4 		$8.88M Buy
943,114
+25,600
+3% +$266K 0.01% 842
2024
Q3 		$9.8M Sell
917,514
-633,662
-41% -$6.9M 0.01% 799
2024
Q2 		$15.4M Buy
1,551,176
+861
+0.1% +$8.84K 0.02% 614
2024
Q1 		$18.3M Buy
1,550,315
+75,103
+5% +$960K 0.02% 562
2023
Q4 		$20.9M Buy
1,475,212
+1,039
+0.1% +$11.8K 0.03% 517
2023
Q3 		$17.9M Buy
1,474,173
+8,309
+0.6% +$107K 0.03% 549
2023
Q2 		$18.4M Sell
1,465,864
-38,854
-3% -$461K 0.02% 603
2023
Q1 		$16.7M Sell
1,504,718
-54,883
-4% -$676K 0.02% 650
2022
Q4 		$19M Buy
1,559,601
+324,248
+26% +$3.65M 0.03% 587
2022
Q3 		$12.9M Buy
1,235,353
+607
+0% +$6.76K 0.02% 724
2022
Q2 		$13.3M Buy
1,234,746
+12,795
+1% +$105K 0.02% 741
2022
Q1 		$11.6M Buy
1,221,951
+199
+0% +$1.87K 0.01% 893
2021
Q4 		$14.1M Buy
1,221,752
+306,228
+33% +$3.41M 0.01% 841
2021
Q3 		$8.74M Sell
915,524
-33,650
-4% -$344K 0.01% 1062
2021
Q2 		$9.15M Sell
949,174
-7,903
-0.8% -$77.1K 0.01% 1054
2021
Q1 		$9.46M Buy
957,077
+698,457
+270% +$10.8M 0.01% 977
2020
Q4 		$5.97M Buy
258,620
+20,820
+9% +$426K 0.01% 1188
2020
Q3 		$3.36M Buy
237,800
+1,700
+0.7% +$24.8K ﹤0.01% 1320
2020
Q2 		$3.56M Buy
236,100
+6,400
+3% +$78K ﹤0.01% 1291
2020
Q1 		$2.12M Hold
229,700
– – ﹤0.01% 1385
2019
Q4 		$2.24M Sell
229,700
-29,700
-11% -$272K ﹤0.01% 1576
2019
Q3 		$2.08M Buy
259,400
+22,200
+9% +$241K ﹤0.01% 1627
2019
Q2 		$2.96M Buy
237,200
+51,600
+28% +$655K ﹤0.01% 1465
2019
Q1 		$2.52M Hold
185,600
– – ﹤0.01% 1501
2018
Q4 		$1.78M Sell
185,600
-35,725
-16% -$393K ﹤0.01% 1609
2018
Q3 		$2.68M Buy
221,325
+700
+0.3% +$9.79K ﹤0.01% 1529
2018
Q2 		$3.45M Buy
220,625
+10,900
+5% +$165K ﹤0.01% 1420
2018
Q1 		$3.15M Buy
209,725
+42,300
+25% +$644K ﹤0.01% 1399
2017
Q4 		$2.41M Buy
167,425
+2,259
+1% +$31K ﹤0.01% 1535
2017
Q3 		$2.49M Buy
165,166
+11,666
+8% +$154K ﹤0.01% 1513
2017
Q2 		$1.55M Buy
153,500
+11,699
+8% +$94.1K ﹤0.01% 1826
2017
Q1 		$1.01M Buy
141,801
+1
+0% +$6 ﹤0.01% 2026
2016
Q4 		$705K Hold
141,800
– – ﹤0.01% 2208
2016
Q3 		$1.05M Sell
141,800
-8,228
-5% -$55.6K ﹤0.01% 1971
2016
Q2 		$819K Buy
150,028
+36,728
+32% +$257K ﹤0.01% 2063
2016
Q1 		$957K Hold
113,300
– – ﹤0.01% 1976
2015
Q4 		$1.1M Hold
113,300
– – ﹤0.01% 1911
2015
Q3 		$1.58M Buy
113,300
+50,730
+81% +$796K ﹤0.01% 1708
2015
Q2 		$885K Buy
+62,570
New +$752K ﹤0.01% 2245

Other funds holding FOLD

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

New York State Common Retirement Fund's FOLD Position: Q2 2026 in Review

New York State Common Retirement Fund sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 88,516 shares — an estimated $1.28M sold.

New York State Common Retirement Fund first reported a position in FOLD in Q2 2015 and held it in 44 quarters. The position peaked at $20.9M in Q4 2023. 1 fund tracked by Wall St. Rank holds FOLD as of Q2 2026.

  • New York State Common Retirement Fund reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • New York State Common Retirement Fund sold 88,516 Amicus Therapeutics shares in Q2 2026, an estimated $1.28M.
  • New York State Common Retirement Fund first reported a position in Amicus Therapeutics in Q2 2015 and held it in 44 quarters.
  • New York State Common Retirement Fund's Amicus Therapeutics position peaked at $20.9M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.